Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)

Next Previous
Search
Trial Profile

Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zanidatamab (Primary) ; Bevacizumab; Capecitabine; Cisplatin; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Jazz Pharmaceuticals Inc

Most Recent Events

  • 23 Apr 2025 According to Jazz Pharmaceuticals plc media release, a rapid oral abstract of this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 30-June 3, 2025, in Chicago and online.
  • 18 Oct 2024 Planned primary completion date changed from 30 Aug 2024 to 31 Jul 2025.
  • 09 Sep 2024 According to Jazz Pharmaceuticals media release, the company will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in Barcelona, Spain.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top